Half-Year 2022 Financial and Clinical Trials Update

Tecentriq Global sales CHFbn CER growth +11% Regional sales CER growth US +13% 2.0 1.6 1.2 0.8 0.4 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 1,758m • US: Growth driven by first-in-class launches in adjuvant PDL1+ NSCLC, in 1L HCC and 1L SCLC • EU: Growth driven by first-in-class launches in adjuvant PDL1+ NSCLC, in 1L HCC and 1L SCLC ● Japan: 11% price cut in Q3 2021 CER-Constant Exchange Rates Europe +19% Japan -7% International +9% Roche 173

View entire presentation